State of New Jersey Common Pension Fund D lessened its position in Pfizer Inc. (NYSE:PFE) by 2.3% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 4,300,000 shares of the biopharmaceutical company’s stock after selling 100,000 shares during the quarter. Pfizer comprises about 0.7% of State of New Jersey Common Pension Fund D’s investment portfolio, making the stock its 24th biggest position. State of New Jersey Common Pension Fund D owned about 0.08% of Pfizer worth $186,276,000 at the end of the most recent reporting period.
A number of other institutional investors and hedge funds have also recently made changes to their positions in the stock. BKD Wealth Advisors LLC boosted its holdings in Pfizer by 2.5% in the fourth quarter. BKD Wealth Advisors LLC now owns 104,315 shares of the biopharmaceutical company’s stock valued at $4,553,000 after purchasing an additional 2,561 shares during the period. Intl Fcstone Inc. lifted its holdings in Pfizer by 21.2% during the 4th quarter. Intl Fcstone Inc. now owns 8,812 shares of the biopharmaceutical company’s stock worth $385,000 after buying an additional 1,540 shares during the last quarter. Navellier & Associates Inc lifted its holdings in Pfizer by 0.7% during the 4th quarter. Navellier & Associates Inc now owns 69,370 shares of the biopharmaceutical company’s stock worth $3,028,000 after buying an additional 487 shares during the last quarter. Daiwa SB Investments Ltd. lifted its holdings in Pfizer by 812.8% during the 4th quarter. Daiwa SB Investments Ltd. now owns 9,950 shares of the biopharmaceutical company’s stock worth $434,000 after buying an additional 8,860 shares during the last quarter. Finally, Rockland Trust Co. lifted its holdings in Pfizer by 0.5% during the 4th quarter. Rockland Trust Co. now owns 169,447 shares of the biopharmaceutical company’s stock worth $7,397,000 after buying an additional 897 shares during the last quarter. Hedge funds and other institutional investors own 71.82% of the company’s stock.
NYSE PFE traded down $0.16 on Friday, hitting $38.09. 9,473,721 shares of the company’s stock were exchanged, compared to its average volume of 23,562,988. The company has a current ratio of 1.54, a quick ratio of 1.27 and a debt-to-equity ratio of 0.60. The firm has a 50-day moving average price of $42.94. Pfizer Inc. has a fifty-two week low of $37.68 and a fifty-two week high of $46.47. The stock has a market cap of $215.67 billion, a price-to-earnings ratio of 12.70, a price-to-earnings-growth ratio of 2.30 and a beta of 0.64.
The firm also recently announced a quarterly dividend, which will be paid on Tuesday, September 3rd. Shareholders of record on Friday, August 2nd will be given a dividend of $0.36 per share. This represents a $1.44 annualized dividend and a yield of 3.78%. The ex-dividend date of this dividend is Thursday, August 1st. Pfizer’s payout ratio is 48.00%.
In other Pfizer news, major shareholder Pfizer Inc bought 50,000 shares of the company’s stock in a transaction on Monday, May 13th. The shares were bought at an average price of $17.00 per share, for a total transaction of $850,000.00. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, EVP Frank A. Damelio sold 153,184 shares of the business’s stock in a transaction that occurred on Tuesday, July 2nd. The stock was sold at an average price of $44.09, for a total value of $6,753,882.56. Following the transaction, the executive vice president now owns 489,647 shares in the company, valued at approximately $21,588,536.23. The disclosure for this sale can be found here. Insiders own 0.09% of the company’s stock.
A number of analysts have issued reports on the company. Goldman Sachs Group reaffirmed a “buy” rating and set a $49.00 price target on shares of Pfizer in a report on Monday, June 17th. Morgan Stanley downgraded Pfizer from an “overweight” rating to an “equal weight” rating and decreased their price target for the stock from $48.00 to $40.00 in a report on Tuesday. Barclays reaffirmed a “hold” rating and set a $41.00 price target on shares of Pfizer in a report on Thursday, May 9th. Zacks Investment Research raised Pfizer from a “sell” rating to a “hold” rating in a report on Wednesday, April 10th. Finally, Bank of America downgraded Pfizer from a “buy” rating to a “neutral” rating in a report on Tuesday. Fifteen analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. The company has an average rating of “Hold” and a consensus target price of $46.44.
Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It offers medicines and vaccines in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases under the Lyrica, Chantix/Champix, Eliquis, Ibrance, Sutent, Xalkori, Inlyta, Xtandi, Enbrel, Xeljanz, Eucrisa, BeneFix, Genotropin, and Refacto AF/Xyntha brands.
Read More: Dividend Achievers
Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE).
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.